PRODUCING GOOD BACTERIA
Probiotics get new name, advance in clinic trial
By Brian Orelli
Friday, February 7, 2014
Orphan-drug specialist, Sigma-Tau Pharmaceuticals Inc. is developing a new class of drugs: live biotherapeutics. As the name implies, Sigma-Tau’s drug candidate, STP206, is a live organism used to repopulate patients’ gastrointestinal tracks. “It’s essentially a probiotic produced in GMP quality,” Sigma-Tau’s CEO Dave Lemus told BioWorld Today.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.